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Background/aim: Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a relatively uncommon and aggressive subset of
pulmonary neuroendocrine tumors, which include typical and atypical carcinoid, and small-cell lung cancer. LCNEC of the lung
accounts for no more than 1% of all lung cancers. LCNECs show features of high-grade neuroendocrine tumors and patients with
LCNEC have a very poor prognosis.
Materials and methods: Twenty-five patients (22 males and 3 females; mean years 60.7; range 48 to 77 years) who underwent pulmonary
resection for large-cell neuroendocrine carcinoma between January 2004 and December 2014 were investigated retrospectively.
Results: Type of surgery, pathologic TNM stage, adjuvant chemotherapy, time of recurrence, site of recurrence, response to treatment,
and long-term results were evaluated. The longest patient follow-up period was 83 months. One-, two-, and three-year survival rates of
these patients were, respectively, 80.95%, 76.47%, and 50%.
Conclusion: Complete surgical resection is the treatment of choice for early-stage LCNEC and chemotherapy after radical surgical
treatment improves survival. Follow-up periods after surgery adjuvant chemotherapy will prevent recurrence and patients may survive
for many years if complete surgical resection and adjuvant chemotherapy are possible.
Key words: Large-cell neuroendocrine carcinoma, resection, adjuvant chemotherapy, radiation therapy

1. Introduction
Large-cell neuroendocrine carcinoma (LCNEC) of the
lung accounts for no more than 1% of all lung cancers.
LCNEC shows features of high-grade neuroendocrine
tumors. LCNECs are aggressive tumors and patients with
LCNEC have a very poor prognosis. The typical histological
features, first described in 1991 (1–3), include large cells
with abundant cytoplasm, a high mitotic rate, extensive
necrosis, and a neuroendocrine growth pattern. The World
Health Organization classified LCNEC as a distinct subtype
of pulmonary large-cell carcinoma in 2004 and therefore as
a subtype of non-small-cell lung carcinoma (NSCLC). On
the other hand, LCNEC was removed from the large cell
carcinoma category and reclassified as a distinct subtype of
neuroendocrine tumors by the WHO classification in 2015
(4). In addition, the clinical and biological characteristics
of LCNEC are similar to those of small cell lung carcinoma
(SCLC). Therefore, there is still no consensus on the
treatment strategy for LCNEC (2). In the present study the
clinicopathological data from 25 patients with LCNEC were
* Correspondence: drfundaincekara@gmail.com
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retrospectively analyzed with the aim of summarizing the
specific clinicopathological features of LCNEC, and the
results of surgical resection as a treatment and the followup period postoperatively were discussed.
2. Materials and methods
Initially, 25 patients who underwent pulmonary resection
for LCNEC are presented and discussed. The authors
investigated the records of 25 patients who were operated
on in the thoracic surgery clinic between January 2004
and December 2014 diagnosed with LCNEC. The mean
age was 60.7 (range: 48–77); the male to female ratio was
22:3. All patients were evaluated based on their patient
history, physical examinations, chest X-rays, chest and
upper abdomen (including the liver and adrenal glands)
computed tomography (CT), and positron emission
tomography (PET)/CT (Figures 1 and 2). Twenty patients
(80%) were smokers. Spirometry tests were routinely
carried out in all of the patients, and preoperative fiberoptic
bronchoscopy (FOB) was also performed. A malignant
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Figure 1. Lesion on the periphery of the right upper lobe, 4 × 3 × 3 cm in size.

Figure 2. Lesion in the center of the right upper lobe, 2.5 × 2 × 2 cm in size.

tumor was confirmed in 5 patients (20%) by bronchoscopy
and in 6 patients (24%) by CT-guided transthoracic needle
biopsy while a definitive diagnosis was achieved by frozen
section (FS) examination in 14 others (56%).
We performed various types of thoracotomies on
these patients based on the localization of the tumor
and we planned pulmonary resection under single-lung
anesthesia. We also performed either an anatomic or
nonanatomic complete resection while preserving most
of the functioning lung tissue. During the operation,
undiagnosed tumors were confirmed by FS examinations.
For centrally located lesions, FS examination of the cut
edges was performed routinely, with the hope of finding a

tumor-free margin of at least 5 mm. In addition, systematic
mediastinal and hilar lymph node sampling was done,
and mediastinal lymph node dissection was carried
out if lymph node metastasis was confirmed by FS after
sampling. The specimens were pathologically examined
and classified as large-cell neuroendocrine carcinoma after
the surgery (Figures 3 and 4).
The following parameters were investigated from the
medical records: patient sex, age, smoking index, tumor
size, tumor location, surgical procedure, pathologic TNM
stage, adjuvant chemotherapy, time of recurrence, site of
recurrence, response to treatment, and patient outcome.
During the follow-up period, these data were prospectively
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Figure 3. Rosettes and palisading patterns in large cell neuroendocrine carcinoma
(HEX200).

Figure 4. Chromogranin positivity in large cell neuroendocrine carcinoma
(ChromograninX400).

recorded in the database, and then all patients were
contacted either in person or by telephone.
We performed routine follow-ups of patients with
LCNEC 4 times per year, checking symptoms and chest
roentgenography. We also performed chest CT at least one
time per year. If abnormal findings were observed, we used
CT to evaluate the hilar-mediastinal and extrathoracic
lymph nodes, the lung field, and the abdomen, and we
used magnetic resonance imaging or CT to evaluate
brain lesions. Bone scintigraphy was used to evaluate
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bone metastases. In some patients, we used positron
emission tomography scans to detect postoperative distant
metastases. If recurrent tumors were suspected, other sites
were also examined.
3. Results
A summary of the 25 patients is presented in Table 1. Left
posteriolateral thoracotomy was performed in 6 patients
and right posteriolateral thoracotomy in 19 patients.
Lobectomy, bilobectomy inferior, pneumonectomy,
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Table 1. A summary of the 25 patients.
Patient Age & sex

Localization & size

Microscopy

Follow-up

1

On the periphery of the right upper lobe, adjacent to 2nd, 3rd ribs, 3
× 3 × 3 cm in size

Chromogranin A+,
NCAM+

Postop 41st month

56-M

2

56-M

On the periphery of the right upper lobe, 5 × 3 × 2 cm in size

Synaptophysin+, NCAM+

Postop 36th month

3

57-M

On the periphery of the right lower lobe, 4 × 3.5 × 3 cm in size

Synaptophysin+, NCAM+

Postop 33rd month

4

50-M

On the periphery of the right lower lobe, 4 × 3 × 3 cm in size

NCAM+
Chromogranin A+,
NCAM+
NCAM+

Postop 27th month
Postop 16th month

5

69-M

On the periphery of the right upper lobe, 1 × 1 × 1 cm in size

6

63-M

In the center of the right upper lobe, 2 × 2 × 2 cm in size

Postop 26th month

7

61-M

On the periphery of the right lower lobe, adjacent to 7th rib, 5 × 5 ×
5.5 cm in size

Synaptophysin+, NCAM+

Postop 15th month

8

61-M

In the center of the right middle& lower lobe, 4 × 4.5 × 4 cm in size

Chromogranin A+,
NCAM+

Postop 8th month exitus

9

63-M

In the center of the right upper lobe, 7 × 10 × 11 cm in size

Chromogranin A+,
NCAM+

Postop 3rd month exitus

10

61-M

On the periphery of the left upper lobe, 2.5 × 1.5 × 1.6 cm in size

NCAM+

Postop 21sth month exitus

11

59-M

On the periphery of the right upper lobe, 2.8 × 2 × 3 cm in size

NCAM+

Postop 3rd month exitus
Postop 41st month

12

48-M

In the center of the left lung, 2 × 3 × 3.5 cm in size

Chromogranin A+,
NCAM+

13

71-F

On the periphery of the left lower lobe, adjacent to 5th rib, 3 × 3.3 ×
4.3 cm in size

Synaptophysin+, NCAM+

Postop 33rd month

14

64-M

On the periphery of the right upper lobe, 9.5 × 8 × 5 cm in size

Synaptophysin+, NCAM+

Postop 29th month

15

62-F

On the periphery of the right lower lobe, 2 × 2 × 1.5 cm in size

Chromogranin A+,
NCAM+

Drop-out

16

77-M

In the center of the right upper lobe, 8 × 5 × 5 cm in size

NCAM+

Drop-out
Drop-out

17

55-F

On the periphery of the right upper lobe, 3 × 3 × 3 cm in size

Chromogranin A+,
NCAM+

18

58-M

On the periphery of the right upper lobe, 4 × 5 × 3 cm in size

Synaptophysin+, NCAM+

Postop 79th month

19

62-M

On the periphery of the right upper lobe, 10 × 11 × 12 cm in size

Chromogranin A+,
NCAM+

Postop 37th month

20

57-M

On the periphery of the left upper lobe, 2 × 1.5 × 1.2 cm in size

Synaptophysin+

Postop 32nd month exitus

21

62-M

On the periphery of the left lower lobe, 1 × 1.3 × 1 cm in size

NCAM+

Postop 45th month exitus

22

59-M

In the center of the right upper lobe, 2.5 × 2 × 2 cm in size

Chromogranin A+,
synaptophysin+

Postop 14th month

23

66-M

On the periphery of the left lower lobe, adjacent to 5th, 8th, 9th ribs,
10 × 13 × 17 cm in size

Synaptophysin+, NCAM+

Postop 11th month exitus

24

57-M

In the center of the right lung, 7 × 4 × 4 cm in size

Chromogranin A+,
synaptophysin+, NCAM+

Postop 83rd month exitus

25

65-M

On the periphery of the right upper lobe, 4 × 3 × 3 cm in size

Chromogranin A+,
synaptophysin+

Postop 3rd month

lobectomy with chest wall resection, and wedge resection
were performed in 14 (56%), 1 (4%), 3 (12%), four (16%),
and 3 patients (12%), respectively.
In one patient, a mass in the opposite lung was
observed at the same time. Therefore, left upper
lobectomy and right upper lobectomy with posteriolateral
thoracotomy were performed. Postoperative pathology
revealed epidermoid carcinoma (stage IIA). The other

side’s postoperative pathology was reported as stage IB
LCNEC. Another patient with left upper lobe epidermoid
carcinoma underwent left posterolateral thoracotomy and
sleeve upper lobectomy; postoperative stage was IB and 3
months after surgery because of a right lower lobe nodule
right posterolateral thoracotomy and lower lobectomy
were performed. Postoperative pathology was reported
as stage IB LCNEC, but the patient died from cardiac
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causes 3 months after the second operation. One of our
patients who had chest wall resection and right lower
lobectomy with posterolateral thoracotomy for LCNEC
had had radiotherapy (RT) because of carcinoma of the
hypopharynx 6 years before. Furthermore, 15 of the 25
patients with an advanced stage of LCNEC underwent
oncological therapy, with 12 receiving only chemotherapy
and three chemoradiotherapy. These 25 patients are
presented in Table 2 according to whether they received
postoperative chemotherapy.
At the time of writing, the longest patient follow-up
period was 83 months, and the newest patient had been
followed up for 3 months. Three of the patients dropped
out during the follow-up period. There was a recurrence
of one patient’s tumor and a rethoracotomy was suggested,
but the patient refused the operation, received adjuvant
chemotherapy and RT, and was still being followed
up. In another patient, with stage IIA LCNEC who
received adjuvant chemoradiotherapy, liver metastases
and widespread bone metastases were observed in the
follow-up period and the patient died 8 months after

surgery. However, the other patients had no distant organ
metastases or local recurrences.
Among the 25 patients with LCNEC, 21 were diagnosed
before 2013, followed up for 1 year; however, four patients
did not complete the follow-up (Table 1). The 1-year
survival rate of these cases was 80.95% (17/21). Seventeen
patients were diagnosed before 2012 and 12 before 2011.
The 2-year survival rate was 76.47% (13/17) and the 3-year
survival rate was 50% (6/12).
4. Discussion
The true incidence of LCNEC is low in all probability,
although it has not been well defined. The incidence of
LCNEC surgically resected lung cancers appears to be
between 2.1% and 3.5% based on the available literature.
The incidence of LCNEC in lung cancers not treated
surgically is unknown but is likely to be higher, given the
aggressive nature of these tumors (5–9). At our institution
from January 2004 through December 2014, there were
25 cases of LCNEC out of 926 surgically resected primary
lung cancers (2.6%).

Table 2. Characteristics of 25 informative patients with large-cell neuroendocrine carcinoma between group with adjuvant chemotherapy
and group without.
Factor

Category

Number
Sex

Adjuvant chemotherapy
+

–

15

10

Male

13

9

Female

2

1

1a

0

3

1b

9

2

2a

2

1

2b

3

2

3a

1

2

Pneumonectomy

2

1

Bilobectomy

1

-

Lobectomy

7

7

Lobectomy with chest wall resection

2

2

Wedge resection

1

2

+

3

-

-

12

7

Unknown

-

3

+

2

1

-

13

6

Unknown

-

3

Pathologic stage

Surgery

Second cancer

Postoperative recurrence
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LCNEC of the lung is a relatively uncommon and
aggressive subset of pulmonary neuroendocrine tumors,
which include typical and atypical carcinoid, and SCLC (1–
3). Men most commonly make up 80% to 90% of patients
with LCNEC (7,10,11). More than 85% of patients have a
history of smoking (10,12). Therefore, smoking appears to
be the primary cause in LCNEC development. The median
age of patients ranged between 62 and 68 years (9,11–14).
Iyoda et al. found a male to female ratio of 11:1 in their
study (15). In our study, the male to female ratio was 22:3;
88% of our patients were male. Twenty-one patients (84%)
had a history of smoking and none of the female patients
were smokers. As recognition and reporting of LCNEC
increases, the epidemiology of this neoplasm will be better
defined, including possible associated environmental and
genetic risk factors.
Regarding the tumor location, LCNECs mostly
present as large primary lung masses in the peripheral
lung fields. They are more frequently identified on chest
radiographs (3,9), as opposed to the central carcinoids
and SCLC site, and therefore clinical symptoms are less
commonly detected. A computed tomography appearance
generally shows a well-defined and lobulated/mass that
resembles other expansively growing tumors, such as
peripheral SCLC, poorly differentiated adenocarcinomas,
and squamous cell carcinomas (16–19). Because of
their peripheral location, diagnosis is most often made
by transthoracic biopsy due to its ease of accessibility.
Regarding 2-[18F]-fluoro-2-deoxy-D-glucose positronemission tomography findings, Kaira et al. reported that
the standardized uptake value peak was significantly
higher in LCNEC as well as in SCLC than in carcinoid,
with a mean value of 13.7 (20). In our study, tumors in 7
cases (28%) were centrally located, while 18 cases (72%)
had peripheral lesions.
LCNEC is rarely diagnosed preoperatively because
the accurate differentiation of LCNEC from other lung
tumors requires a careful review of the pathologic
specimen. Diagnosis of LCNEC is often a difficult
task that requires histological analysis, cytological
evaluation, and immunohistochemistry (21–23). In
addition, due to the small specimen, tissue extrusion,
and deformation, immunohistochemistry is difficult.
Therefore, LCNEC has been usually diagnosed in surgical
specimens postoperatively. In our study, the pathology
of the FOB biopsy was reported as LCNEC in 1 patient,
neuroendocrine carcinoma in 2, and NSCLC in 2.
Transthoracic biopsy pathology in 4 patients was NSCLC,
while it was neuroendocrine carcinoma in 1 patient.
FS examination of the remaining 14 patients during the
operation revealed malignant tumors. Only one case (4%)
was confirmed or considered to be LCNEC by FOB biopsy.
The other 24 patients were diagnosed by postoperative
surgical specimen.

Before the diagnosis of LCNEC, neuroendocrine
differentiation must be confirmed by light microscopy
and subsequently distinguished from typical carcinoma,
atypical carcinoma, and SCLC by size, presence or absence
of necrosis, and mitotic rate. LCNEC shows histological
features such as organoid nesting, trabecular growth,
rosettes, and perilobular palisading patterns, suggesting
neuroendocrine differentiation. The tumor cells are
generally large, with moderate to abundant cytoplasm.
Nucleoli are frequent and prominent and their presence
facilitates separation from small cell carcinoma. Mitotic
counts are typically 11 or more (average 75) per 2 mm2
of viable tumor. Confirmation of neuroendocrine
differentiation is required using immunohistochemical
markers such as chromogranin, synaptophysin, and
neural cell adhesion molecule (NCAM). One positive
marker is sufficient if the staining is clear cut. Rossi et al.
were the first to report the percentage of chromogranin
A (65%), synaptophysin (53%), and NCAM (93%) in
LCNEC (24). In our study, NCAM 92%, synaptophysine
40%, chromogranin A 44%, and 3 marker positivity only
in 1 patient (4%) were observed. Postoperative pathologic
staging was evaluated as stage IA in 3 patients, while 11
patients had stage IB, 3 patients had stage IIA, 5 patients
had IIB, and the remaining 3 patients had stage IIIA.
The optimal treatment for LCNEC has not been
determined. Zacharias et al. reported that patients with
LCNECs, which are aggressive tumors, had a good
prognosis if they underwent complete tumor resection
with systematic nodal dissection (25). Iyoda et al. revealed
that adjuvant chemotherapy was effective for treating
patients with LCNEC (26). Rossi et al. and Iyoda et al.
showed that patients receiving adjuvant chemotherapy had
a good prognosis after complete surgical resection and that
adjuvant chemotherapy was promising for patients with
LCNEC (24,27). We performed complete R0 resection
of the tumor with systematic nodal dissection in our 22
patients because of LCNEC for 10 years. In 3 patients
operated on previously, wedge resection was performed
due to the limited respiratory reserve. Pneumonectomy,
bilobectomy inferior, lobectomy, and lobectomy with
resection of the chest wall were performed in patients
with complete tumor resection. Furthermore, 15 of the
25 patients with an advanced stage of LCNEC underwent
oncological therapy; 15 received chemotherapy (Table
2) and four chemoradiotherapy. Three patients had
palliative radiotherapy. Although it has been reported that
LCNEC patients have frequent recurrent tumors and very
poor prognoses, Iyoda et al. determined that platinumbased adjuvant chemotherapy after surgery significantly
prevents recurrence and that recurrent tumors might also
be responsive to platinum-based chemotherapy, radiation
therapy, or the combination of the two (15). The role of

1813

İNCEKARA et al. / Turk J Med Sci
adjuvant therapy for LCNEC should be examined in largecenter prospective, randomized trials.
The 1-, 2-, and 3-year survival rates in our study were
80.95%, 76.47%, and 50%, respectively. There were four
patients in 1-year follow-up, four in 2-year follow-up, and
six in 3-year follow-up who did not complete the follow-up
time. Compared to our study results, Varlotto et al. found 1-,
2-, and 4-year survival rates of, respectively, 76%, 56%, and
41% (28). In a retrospective study by Liang et al., the 1-year
survival rate of their patients was 57.8% (48/83) (29).
LCNEC of the lung is an uncommon but aggressive
neoplasm with a poor prognosis. No studies have
established the optimal treatment for patients with

LCNEC. These tumors should be classified separately
from grade III neuroendocrine carcinoma large-cell type,
part of the neuroendocrine spectrum of lung cancer.
The optimal approach to LCNEC is surgical complete
resection of the tumor, and the diameter, stage, and lymph
node involvement of the tumor are among the factors
that determine the prognosis. Chemotherapy after radical
surgical treatment improves survival. Our study showed
that adjuvant chemotherapy after surgery yielded better
results. Despite the aggressive behavior of this type of
tumor being associated with a poor prognosis, patients
will survive for many years if complete surgical resection
and adjuvant chemotherapy are possible.
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